Investment bank Peregrine Corporate has upped its stake in Prima BioMed to around 14 per cent on the back of a AUD$7.2 million share placement of 11.62 million ordinary shares.

Gene silencing specialist Benitec has denied rumours that it is to relocate from its IMB (Institute for Molecular Bioscience) base in Queensland to the US, claiming that North American media misreported the situation.

As part of its strategy to move into the Asian region, Norwood Abbey has appointed a new commercial partner to market its range of laser assisted drug delivery products.

Researchers at the Prince of Wales Hospital have established a link between breast cancer and the human form of a mouse virus.

Drug discovery biotech Antisense Therapeutics (ASX:ANP) has added AUD$5 million to its coffers with the placement of 38.5 million new shares to the institutional and specialist investor market.

Peptech is to lose its managing director Stephen Kwik in the first glimpse of what chairman Mel Bridges has dubbed a "broadening and deepening of scope" for the therapeutic peptide and protein biotech.

Buoyed by the data from a recent research paper out of Cambridge University, gene discovery biotech AGT Biosciences has announced it has broadened its patent covering PARL (formerly gene AGT203) to cover cancer, aging and some other diseases.

A just-released BioForum report by business watchers PricewaterhouseCoopers has talked up the life sciences sector, based on a strong Q4 performance and positive investor sentiment thanks to better than average results compared to the five previous quarters.

According to John E Davies, general manager of e-business channels and marketing at Intel, the world offers computer companies four big targets when it comes to networked and clustered computers: energy; manufacturing, financial services -- and bioinformatics.

Sydney's Victor Chang Cardiac Research Institute has signed a deal to investigate a tissue restorative agent, BDM-K, for Melbourne biopharma BioDiem

The Australian Proteome Analysis Facility (APAF) has "dramatically increased its throughput capability" with the installation of a new Applied Biosystems 4700 Proteomics Discovery System.